Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib
Journal of Oncology Pharmacy Practice, vol.26, no.2, pp.478-480, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 26 Issue: 2
- Publication Date: 2020
- Doi Number: 10.1177/1078155219852146
- Journal Name: Journal of Oncology Pharmacy Practice
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Page Numbers: pp.478-480
- Keywords: cardiomyopathy, CLL, Ibrutinib, left ventricular dysfunction
- Trakya University Affiliated: Yes
Abstract
Introduction: Ibrutinib, an oral inhibitor of Bruton’s tyrosine kinase, has altered the treatment perspective of chronic lymphocytic leukemia and showed modest activity against several types of non-Hodgkin’s lymphomas. According to phase studies and real-world data, reported serious adverse effects included atrial fibrillation, diarrhea, and bleeding diathesis. However, heart failure was not reported to be a probable adverse effect linked with ibrutinib. Case report: In this paper, we present a 66-year-old female chronic lymphocytic leukemia patient who developed significant and symptomatic left ventricular dysfunction at the 13th month of ibrutinib treatment. Management and outcome: Following cessation of ibrutinib, ejection fraction and clinical findings of the left ventricular dysfunction alleviated. Discussion: Although the use of ibrutinib is generally well tolerated, cardiac functions should be monitored occasionally in all patients.